美罗培南与亚胺培南-西司他丁钠治疗下呼吸道感染的临床研究  

Clinical Research on Meropenem and Imipenem-Cilastatin Sodium in the Treatment of Lower Respiratory Tract Infection

作　　者：张秀凤[1] 

机构地区：[1]中国人民解放军第476医院呼吸内科,福建福州350002

出　　处：《中国卫生标准管理》2017年第19期102-103,共2页China Health Standard Management

摘　　要：目的对比治疗下呼吸道感染采用美罗培南和亚胺培南-西司他丁钠的临床效果。方法选取我院2012年4月—2015年9月纳入的下呼吸道感染患者134例作为研究对象。按照入院顺序,将其分为两组,其中67例患者采用美罗培南治疗作为观察组,另67例患者采用亚胺培南-西司他丁钠治疗作为对照组,比较两组患者临床疗效。结果观察组的总有效率为94.03%,高于对照组的83.58%。观察组不良反应发生率为13.43%,低于对照组的25.37%。两组数据对比,差异具有统计学意义(P<0.05)。结论临床上使用美罗培南进行治疗下呼吸道感染效果更显著,安全性更高。Objective To compare the clinical effect of meropenem and imipenem cilastatin sodium in the treatment of lower respiratory tract infection. Methods 134 cases of lower respiratory tract infections in our hospital from April 2012 to September 2015 were selected as the research object. According to the order of admission, they were divided into two groups, 67 cases were treated with meropenem treatment as the observation group, 67 patients were treated with imipenem and ulinastatin as the control group, the clinical efficacy of the two groups was compared. Results The total effective rate of the observation group was 94.03%, higher than 83.58% of the control group. The incidence of adverse reactions in observation group was 13.43%, which was lower than 25.37% in control group. The difference between the two groups was statistically signifcant （P 〈 0.05）. Conclusion Meropenem has an obvious effect in the treatment of lower respiratory tract infection and improves the clinical safety.

关 键 词：临床疗效 美罗培南 亚胺培南-西司他丁钠 下呼吸道感染 

分 类 号：R56[医药卫生—呼吸系统]